Bone Biologics (BBLG) Net Margin (2016 - 2017)

Bone Biologics (BBLG) has disclosed Net Margin for 2 consecutive years, with 106.19% as the latest value for Q2 2017.

  • On a quarterly basis, Net Margin fell 141097.0% to 106.19% in Q2 2017 year-over-year; TTM through Dec 2017 was 410.11%, a 211182.0% decrease, with the full-year FY2025 number at 2468.41%, up 439392.0% from a year prior.
  • Net Margin was 106.19% for Q2 2017 at Bone Biologics, down from 383.36% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 3954.93% in Q1 2016 to a low of 106.19% in Q2 2017.